The Center for Cancer Research, National Cancer Institute, is now accepting participants for a pilot study evaluating the effects of Metformin in patients with LFS.
- Metformin is currently being studied in over sixty clinical trials of cancers including breast, colon, and uterine cancer, among others. This is the first study in patients with Li-Fraumeni Syndrome investigating the effects of Metformin in this special population.
- Evidence from research studies suggests people with diabetes taking Metformin may have a reduced risk of developing, and dying from, cancer. Metformin has also been widely used in people without diabetes and is well tolerated with minimal side effects.
- The study duration is 20 weeks long and will require some travel to NIH in Bethesda, MD.
- If you are interested in learning more about this study, please contact Dr. Farzana Walcott, Lead Associate Investigator at farzana.walcott@nih.gov or 240-276-7661. Further information can also be found on the NCI Clinical Center webpage and www.clinicaltrials.gov.